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Wegener's Granulomatosis 
Background  
1. Form of systemic vasculitis with "classic" and "limited" forms  
2. Classic Wegener's involves a triad of upper respiratory disease, lower respiratory 
disease and glomerulonephritis
1-6
  
o Upper respiratory disease:  
 Sinusitis, nasal obstruction, otitis media, mastoiditis 
o Lower respiratory disease:  
 Cough, dyspnea, hemoptysis 
o Glomerulonephritis (GN):  
 Asymptomatic, acute renal failure 
3. Limited form - isolated upper or lower respiratory disease  
o Occurs in approx 25% of cases 
o Up to 80% will eventually develop GN 
 
Pathophysiology  
1. Type III immune complex mediated hypersensitivity  
o Results in necrotizing vasculitis of small and medium arteries 
2. Prevalence - 3 per 100,0002  
3. Risk factors: males, >50% Caucasian, age 50-60 years6  
4. Morbidity:1-7  
o Musculoskeletal:  
 Myalgias 
 Arthralgias 
 Arthritis 
o Venous thromboembolism common (7 per 100 person-years) 
o Respiratory:  
 Alveolar hemorrhage 
o Dermatologic:  
 Vesicular and hemorrhagic lesions 
 Palpable purpura 
o Renal:  
 Renal failure 
 Rapidly progressive glomerulonephritis 
o Cardiac:  
 Dilated cardiomyopathy 
 Pericarditis 
 Conduction abnormalities 
o Neurologic:  
 Mononeuritis multiplex 
 CNS lesions 
 Ocular abnormalities (scleritis, corneal ulcer, uveitis, optic neuropathy) 
o GI, GU and reproductive manifestations less common 
5. Mortality:  
o If untreated:  
 90% mortality rate at 2 years 
o Treated with cyclophosphamide:  
 Mortality rate 20-28% at 5 years and 35% at 10 years 
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o Other therapies may have better prognosis 
o Chronic renal failure most common cause of death
8
  
 
Diagnostics  
1. History2,6  
o Nonspecific complaints:  
 Night sweats, anorexia, arthralgias, wt loss common, fever (90%) 
o Pulmonary involvement (100%)  
 May be asymptomatic in 1/3 in limited form 
o Upper or lower airway dz  
 Hemoptysis, sinusitis, chronic nasal discharge, dyspnea 
o Acute or chronic renal failure 
2. Physical exam2,6,7  
o Skin:  
 Vasculitic lesions, rash, palpable purpura, subcutaneous nodules 
o HEENT:  
 Mucosal ulcerations, exophthalmos, saddle nose deformity, hearing 
loss, otitis, neuritis, hyperplastic gingivitis 
o Lung:  
 Pneumonitis and pleural effusion 
o Tumor-like masses in lung, breast and kidney 
3. Diagnostic testing2,3,6  
o Laboratory evaluation 
o Anti-neutrophil cytoplasmic antibodies (ANCA): (SOR:B)  
 Indirect immunofluorescence: c-ANCA or p-ANCA patterns 
 Enzyme-linked immunosorbent assay (ELISA) of PR3-ANCA and 
MPO-ANCA antibodies 
 Up to 90% ANCA positive with active generalized disease  
 Only 60-70% sensitive with limited form 
o Microscopic hematuria 
o Tissue biopsy at site of active disease used to confirm diagnosis
2
  
o Skin lesions preferred due to less invasive procedure 
4. Diagnostic imaging  
o Chest x-ray  
 May show cavitary nodules, alveolar or pleural opacities 
o Chest CT  
 May show wedge shaped densities, narrowing of bronchial lumen, 
enlarged peripheral pulmonary arteries, hemorrhage or infiltrates 
o Angiography  
 May show aneurysmal dilation 
o Echocardiography  
 May show systolic dysfunction or pericardial effusion 
5. Diagnostic "Criteria"9  
o Nasal or oral inflammation  
 Painful or painless ulcers or purulent or bloody nasal discharge 
o Abnormal CXR showing nodules, fixed infiltrate or cavities 
o Urinary sediment  
 Microscopic hematuria >5 RBCs/hpf with or without RBC casts 
o Granulomatous inflammation on biopsy of artery or perivascular area 
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o 88.2% sensitivity and 92% specificity 
6. Other testing:  
o CBC  
 Leukocytosis, thrombocytosis, normochromic normocytic anemia 
o ESR (marked elevation) 
o Serum creatinine (marked elevation) 
o UA (red cells, red cell casts, proteinuria) 
o RF (negative) 
o ANA (negative) 
o Hepatitis serology (negative)
2
 
7. Treatment may be predicated on positive ANCA results  
o Seek histopathologic confirmation before beginning long term treatment 
 
Differential Diagnosis  
1. Key DDx  
o Polyarteritis Nodosa (PAN)  
 Auto-antibodies rarely present 
 Non-granulomatous 
o Anti-GBM antibody (Goodpasture's) dz  
 Positive anti-GBM antibody 
 Negative ANCA serology 
 Limited to pulmonary and renal involvement 
o Churg-Strauss Syndrome  
 Typically c-ANCA negative 
o Systemic lupus erythematosus  
 Negative ANCA serology 
2. Extensive DDx  
o Sjögren's syndrome  
 ANCA negative 
 Lacrimal and salivary gland involvement 
o Microscopic polyangiitis  
 Typically c-ANCA negative 
o Renal limited vasculitis  
 Negative ANCA serology 
 No systemic manifestations  
o Drug-induced ANCA associated vasculitis  
 Propylthiouracil, hydralazine, minocycline 
o Inflammatory myopathies  
 Primarily muscle and skin involvement 
 No renal and pulmonary Sx 
o Rhinitis  
 Limited to nose 
 No renal and pulmonary Sx 
 
Therapeutics
10
  
1. Initial therapy  
o High-dose steroids (PO or pulse IV) and cyclophosphamide (PO or pulse IV) 
until remission induced  
 Remission may take 3-6 months  
Wegener’s Granulomatosis Page 4 of 5    4.27.09 
o Methylprednisolone or prednisone: (SOR:B)  
 Pulse therapy - all patients with necrotizing/crescentic GN or severe 
respiratory dz  
 7-15 mg/kg (max 500-1000 mg/day) for 3 days 
 PO therapy - on day one or after pulse therapy (if pulse therapy 
indicated)  
 1 mg/kg per day for 2-4 weeks (max 80 mg/d) 
 Tapered to 20 mg per day by the end of 8-10 weeks 
 Maintain 20 mg/d x2 weeks 
 Then reduce dose by 2.5 mg/week until taking 10 mg/d 
 Then reduce dose by 1 mg/week until off 
o Cyclophosphamide (CYC) for 3-6 months to induce remission: (SOR:B)  
 PO therapy (1.5-2 mg/kg per day) 
 Pulse IV (0.5-1 g/sq.meter body surface area every few weeks)  
 PO therapy has led to fewer relapses  
 Drink eight 8 oz glasses of water per day – avoids cystitis 
 CBC every 2 weeks and UA monthly 
 Pneumocystis carinii prophylaxis - always 
o Methotrexate may be substituted for cyclophosphamide in mild disease if 
serum creatinine <2 mg/dL (SOR:B) 
 PO therapy weekly:  
 Start with 0.3 mg/kg, max 15 mg 
 Increase by 2.5 mg each week, to max 20-25 mg/week 
 Combine with steroids as with CYC  
2. Once proteinuria or hematuria develop - rapid progression to renal failure 
3. Maintenance therapy (SOR:B)  
o Cytotoxic therapy with methotrexate OR azathioprine preferred over 
cyclophosphamide  
 Usually continued 1-2 years after remission 
 Methotrexate:  
 PO weekly 0.3 mg/kg, max 15 mg 
 Increase by 2.5 mg each week to max 20-25 mg/week  
 Azathioprine:  
 2 mg/kg/day 
 Decrease to 1.5 mg/kg per day at 1 year 
o Glucocorticoids  
 May be slowly tapered after 1 month or maintained on low 
dose/alternate day dosing for duration of therapy 
o Trimethoprim/Sulfamethoxazole (SOR:C) 
 Mechanism of action unclear 
 Proven as maintenance therapy in RCTs up to 2 years out 
 Use only in mild cases; weigh benefits and risk  
 
Follow-Up  
1. Serial ANCA titers may predict relapse - measured every 2 months  
o Predictive value of increased ANCA titer for relapse  
 57% for cytoplasmic/classic ANCA 
 71% for PR3-ANCA 
 100% for MPO-ANCA 
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2. Referral to rheumatologist, pulmonologist or nephrologist – based on 
clinical/objective evaluation 
3. Continue monitoring CBC and UA after CYC discontinued 
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